MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ
1.010
-0.020
-1.94%
Closed 16:00 12/07 EST
OPEN
1.060
PREV CLOSE
1.030
HIGH
1.070
LOW
1.000
VOLUME
386.62K
TURNOVER
0
52 WEEK HIGH
4.130
52 WEEK LOW
0.8089
MARKET CAP
32.38M
P/E (TTM)
-0.6522
1D
5D
1M
3M
1Y
5Y
SELLAS Life Sciences Announces Positive Recommendation From REGAL Independent Data Monitoring Committee Of Galinpepimut-S In Acute Myeloid Leukemia
Independent data monitoring committee (idmc) recommended that the phase 3 regal clinical trial of galinpepimut-s in acute myeloid leukemia (aml) continue without modifications. Idmc expressed satisfaction with speed of enrollment and high study integrity. Most current survival data to be reviewed at next idmc meeting in q1 2024.
Benzinga · 3d ago
Weekly Report: what happened at SLS last week (1127-1201)?
Weekly Report · 3d ago
Analysts’ Top Healthcare Picks: Olema Pharmaceuticals (OLMA), SELLAS Life Sciences Group (SLS)
TipRanks · 11/30 15:40
Weekly Report: what happened at SLS last week (1120-1124)?
Weekly Report · 11/27 10:04
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target
Benzinga · 11/22 16:21
Weekly Report: what happened at SLS last week (1113-1117)?
Weekly Report · 11/20 10:03
SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback On Chemistry, Manufacturing, And Controls Biologics License Application Filing Strategy For Galinpepimut-S
Benzinga · 11/13 13:51
Weekly Report: what happened at SLS last week (1106-1110)?
Weekly Report · 11/13 10:00
More
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in 20 or more cancer types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers, and solid tumor indications. The Company is also developing GFH009, a small molecule, selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Webull offers Sellas Life Sciences Group Inc stock information, including NASDAQ: SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.